Roivant Sciences (NASDAQ:ROIV) Insider Sells $27,492,361.50 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Frank Torti sold 1,012,610 shares of Roivant Sciences stock in a transaction on Friday, February 20th. The stock was sold at an average price of $27.15, for a total transaction of $27,492,361.50. Following the sale, the insider owned 13,736,547 shares of the company’s stock, valued at $372,947,251.05. The trade was a 6.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Frank Torti also recently made the following trade(s):

• On Thursday, February 19th, Frank Torti sold 1,400,000 shares of Roivant Sciences stock. The shares were sold at an average price of $27.42, for a total value of $38,388,000.00.
• On Monday, February 23rd, Frank Torti sold 587,390 shares of Roivant Sciences stock. The stock was sold at an average price of $27.51, for a total transaction of $16,159,098.90.

Roivant Sciences Stock Performance

Shares of ROIV stock traded up $0.61 on Monday, reaching $27.76. 4,414,766 shares of the company were exchanged, compared to its average volume of 6,823,292. The company has a market cap of $19.87 billion, a price-to-earnings ratio of -23.73 and a beta of 1.22. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $27.94. The business has a 50-day moving average price of $23.44 and a 200 day moving average price of $19.07.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Oregon Public Employees Retirement Fund grew its stake in Roivant Sciences by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after acquiring an additional 500 shares during the period. Bank of Montreal Can increased its position in shares of Roivant Sciences by 1.3% in the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock worth $868,000 after acquiring an additional 516 shares in the last quarter. Bessemer Group Inc. raised its position in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Allworth Financial LP boosted its holdings in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares during the period. Finally, Fifth Third Bancorp grew its holdings in Roivant Sciences by 15.8% during the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after purchasing an additional 588 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Guggenheim raised their price objective on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Weiss Ratings lowered shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, February 9th. Leerink Partners boosted their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. HC Wainwright boosted their target price on Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $30.00 price objective on shares of Roivant Sciences in a research report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $28.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.